Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer

KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of potential therapeutics. One hundred eighty-five cons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Wang, Yudong, Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Hess, Kenneth, Broaddus, Russell, Shan, Baoen, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Lu, Charles, Papadimitrakopoulou, Vali, Heymach, John, Meric-Bernstam, Funda, Fu, Siqing
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161801/
https://ncbi.nlm.nih.gov/pubmed/30279957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25947
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars